Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

1. Arroyo González, R.
2. Kita, M.
3. Crayton, H.
4. Havrdova, E.
5. Margolin, D.H.
6. Lake, S.L.
7. Giovannoni, G.